Creat Group-B(06628) partner Inhibrx announced positive results from the Phase II clinical trial of ozekibart in the treatment of chondrosarcoma, and plans to submit the BLA performance progress in 2026.

Chi-Next Finance APP News, Creat Group-B (06628) announced that their partner, Inhibrx Biosciences, Inc. (Inhibrx, Nasdaq: INBX), has released the positive primary results of the registration clinical study ChonDRAgon (n=206). The study evaluated the efficacy of ozekibart (INBRX-109) as a monotherapy compared to placebo in patients with advanced or metastatic, unresectable chondrosarcoma. Based on these results, Inhibrx plans to submit a marketing authorization application for ozekibart chondrosarcoma indication to US regulatory authorities by the end of June 2026. According to a licensing agreement signed by the company through its wholly-owned subsidiary Hangzhou Yianjishi Biosciences Co., Ltd. (HJB), the company has exclusive development and commercialization rights for ozekibart (INBRX-109) in Mainland China, the Hong Kong Special Administrative Region, the Macau Special Administrative Region, and Taiwan.